Novartis AG ADR (NVS)vsPersonalis Inc (PSNL)
NVS
Novartis AG ADR
$145.46
+1.32%
HEALTHCARE · Cap: $271.25B
PSNL
Personalis Inc
$16.46
-0.66%
HEALTHCARE · Cap: $1.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 81275% more annual revenue ($56.69B vs $69.67M). NVS leads profitability with a 22.5% profit margin vs -153.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PSNL
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$145.46
$52.06 premium
Margin of Safety
-68.2%
Fair Value
$5.29
Current Price
$16.46
$11.17 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 30.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -37.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PSNL
The strongest argument for PSNL centers on Revenue Growth, Debt/Equity. Revenue growth of 30.0% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PSNL
The primary concerns for PSNL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
NVS profiles as a value stock while PSNL is a growth play — different risk/reward profiles.
PSNL carries more volatility with a beta of 2.32 — expect wider price swings.
PSNL is growing revenue faster at 30.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 27/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Personalis Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?